Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 8/20 | 0.54 |
| ▸ | MMP9 | P14780 | 6/20 | 0.54 |
| ▸ | MMP1 | P03956 | 3/20 | 0.54 |
| ▸ | MMP13 | P45452 | 3/20 | 0.54 |
| ▸ | MMP3 | P08254 | 2/20 | 0.54 |
| ▸ | MMP7 | P09237 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | EEF2K | O00418 | 1/20 | 0.48 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.48 |
| ▸ | MMP8 | P22894 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | MMP14 | P50281 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10102615 | 0.89 | SLC1A3 (0.56) | SLC1A3SLC1A2SLC1A1MMP2MMP9 | |
| SCHEMBL2053891 | 0.89 | SLC1A3 (0.56) | SLC1A3SLC1A2SLC1A1MMP2MMP9 | |
| SCHEMBL4824739 | 0.87 | MEN1 (0.58) | MMP2MMP9MEN1KMT2AMAPT | |
| SCHEMBL8512082 | 0.85 | SLC1A3 (0.60) | SLC1A3SLC1A2SLC1A1MMP2MMP9 | |
| SCHEMBL2161085 | 0.84 | ALDH1A1 (0.62) | SLC1A3SLC1A2SLC1A1MMP2MMP9 | |
| SCHEMBL1000596 | 0.84 | ALDH1A1 (0.62) | SLC1A3SLC1A2SLC1A1MMP2MMP9 | |
| SCHEMBL2161104 | 0.84 | ALDH1A1 (0.62) | SLC1A3SLC1A2SLC1A1MMP2MMP9 | |
| SCHEMBL7018767 | 0.82 | GFER (0.57) | MMP2MMP9MMP1MMP13MMP3 | |
| SCHEMBL30702481 | 0.81 | SLC1A3 (0.47) | SLC1A3SLC1A2SLC1A1MMP2MMP9 | |
| SCHEMBL7383649 | 0.81 | SLC1A3 (0.59) | SLC1A3SLC1A2SLC1A1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2366704-B1 | Inhibitors of serine proteases | VERTEX PHARMA (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2631238-A1 | Spirocyclic inhibitors of serine proteases for the treatment of hcv infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8372873-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| EP-1917269-B1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMA (US) | 2011-10-26 | — | — | EP | disclosed |
| EP-2366704-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-2364984-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-7964624-B1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | SLC1A3 1847/4885SLC1A2 3159/4885SLC1A1 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.